Samsung Biologics names John Rim as CEO and President
pharmafile | December 17, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Samsung BioLogics
Samsung Biologics has appointed John Rim as the company’s President and CEO. The appointment was made effective immediately and formalised via the company’s board of directors meeting yesterday.
Before his appointment as CEO, Rim was Samsung Biologics’ Executive Vice President, and was a key senior leadership contributor in driving the company’s success through a strong focus on client satisfaction and global business acumen. He was also instrumental in the rapid expansion of the company’s manufacturing portfolio and the continuous operational excellence in Plant 3, the world’s largest manufacturing capacity at a single site. As CEO, Rim will continue to serve on the company’s board as an inside director, offering his in-depth industry experience and global background.
With over 30 years’ experience in the biopharmaceutical industry, Rim began his career as a management consultant with Booz, Allen & Hamilton, consulting to pharmaceutical companies in the US and Europe. He has also held numerous senior leadership roles with Astellas Pharmaceuticals, and, before joining Samsung Biologics in 2018, worked for Genentech/Roche in a variety of senior global leadership roles in Technical Operations, Product Development, and Research and Development in the US and Europe.
Rim himself said: “I am deeply grateful and excited by the opportunity to lead Samsung Biologics into the next decade. This is an extraordinary company, unparalleled in its phenomenal growth and dedication to client satisfaction, made possible by the company’s unrelenting vision and passion, and business execution by great people whom I will have the privilege to lead as CEO.”
Related Content
Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics
Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing …
AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal
AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to …
Samsung BioLogics delisted over accounting violations
South Korean firm Samsung BioLogics has been delisted from the South Korean stock exchange. The …
